We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
APIXABAN SANDOZ (Sandoz Pty Ltd)
Product name
APIXABAN SANDOZ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
136 (255 working days)
Active ingredients
apixaban
Registration type
New generic medicine
Indication
APIXABAN SANDOZ is indicated for the prevention of venous thromboembolic events(VTE) in adult patients who have undergone elective total hip or total knee replacement surgery.
APIXABAN SANDOZ is indicated for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke.
APIXABAN SANDOZ is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adult patients.
APIXABAN SANDOZ is indicated for the prevention of recurrent DVT and PE in adult patients.